Analysts noted that they envision "durable growth" in Veracyte's Afirma and Decipher Prostate tests and "long-term growth potential" from its MRD testing business.

The firm's total revenues increased 5 percent year over year, leading it to raise the midpoint of its full-year EPS guidance.

Aspira can now offer the test, intended for assessing ovarian cancer risk in women with an adnexal mass, to patients in New York state.

Retirements and the outcomes of a handful of close races could reshape congressional committees tasked with oversight of issues important to labs.

According to the government, Tina Ball and her lab company knowingly billed North Carolina Medicaid for urine drug tests that were medically unnecessary.

NEW YORK – BioMérieux announced on Tuesday that it has obtained the CE mark for an assay to detect vitamin B12. The automated, quantitative test runs on the firm's Vidas immunoanalyzers.

The firm's analysts wrote that they see stability in Revvity's diagnostics business and growth above peers in its life sciences and reagents business.

Last week, readers were most interested in a story about Roche and BARDA teaming up to develop diagnostic tests for traumatic brain injuries.

The company continues to build validation data and believes its lower cost proposition can help it gain leverage in the European market where molecular tests are not reimbursed.

The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

The researchers used the CellSearch assay to measure circulating tumor cells and determine the response to certain treatments as well as survival outcomes.